Cited by 293Renin-Angiotensin System StudiesBlood Pressure and Hypertension StudiesChronic Kidney Disease and Diabetes

The DOI matches its Crossref record; 88 of the 89 references it cites were found in a registry or an index.

Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetes

Jandeleit-Dahm, Karin AM, Tikellis, Christos, Reid, Christopher M, Johnston, Colin I, Cooper, Mark E·2005·Journal of Hypertension

DOI 10.1097/01.hjh.0000160198.05416.72

Open this paper in CoChat — free account

Abstract

Recent trials have suggested that inhibitors of the renin-angiotensin system (RAS), such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), may reduce the incidence of new-onset diabetes in patients with or without hypertension and at high risk of developing diabetes. In this review, we critically evaluate the evidence from recent clinical trials for such a potential preventive effect of ACE inhibitors and ARBs, including a meta-analysis of these recent trials. The reduced incidence of diabetes in patients at high risk of developing diabetes by ACE inhibitors or ARBs has been explained by haemodynamic effects, such as improved delivery of insulin and glucose to the peripheral skeletal muscle, and non-haemodynamic effects, including direct effects on glucose transport and insulin signalling pathways, all of which decrease insulin resistance. There is now evidence that the pancreas may contain an in situ active RAS, which appears to be upregulated in an animal model of type 2 diabetes. Thus, ACE inhibitors and ARBs may act by attenuating the deleterious effect of angiotensin II on vasoconstriction, fibrosis, inflammation, apoptosis and beta-cell death in the pancreas, thereby protecting a critical beta-cell mass essential for insulin production. New evidence is presented that ACE inhibitors and ARBs may delay or prevent the development of insulin resistance and diabetes, for which novel mechanisms are suggested. The actions of agents that interrupt the RAS on insulin resistance, obesity and diabetes warrant further investigation in other animal models. Prospective clinical studies with the primary endpoint of the prevention of diabetes are now indicated to (i) further explore whether the inhibitors of the RAS are superior compared to other antihypertensive agents such as calcium channel blockers (CCBs) and (ii) to evaluate the potential beneficial effects of combination antihypertensive regimens on the development of diabetes.

Integrity signals

Registry

Crossref · 10.1097/01.hjh.0000160198.05416.72

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease
DeFronzo, R. A., & Ferrannini, E. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.173 · Cited by 4,555
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy
(2000) · The Lancet · doi:10.1016/s0140-6736(99)12323-7 · Cited by 3,179
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
(2001) · The Lancet · doi:10.1016/s0140-6736(01)06178-5 · Cited by 3,178
Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells.
Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D., & Alexander, R. W. (1994) · Circulation Research · doi:10.1161/01.res.74.6.1141 · Cited by 2,735
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14286-9 · Cited by 2,142
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial
Hansson, L., Lindholm, L. H., NISKANEN, L. K., Lanke, J., Hedner, T., Niklason, A., LUOMANMÄKI, K., Dahlöf, B., Fairé, U. D., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 1,991
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
Pfeffer, M. A., Swedberg, K. B., Granger, C. B., Held, P., McMurray, J. J. V., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,895
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B., et al. (1998) · BMJ · doi:10.1136/bmj.317.7160.713 · Cited by 1,789
Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
Hansson, L., Lindholm, L. H., Ekbom, T., Dahlöf, B., Lanke, J., Scherstén, B., Wester, P.-O., Hedner, T., & Fairé, U. D. (1999) · The Lancet · doi:10.1016/s0140-6736(99)10327-1 · Cited by 1,442
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 1,406
Diabetes, Hypertension, and Cardiovascular Disease
Sowers, J. R., Epstein, M., & Frohlich, E. D. (2001) · Hypertension · doi:10.1161/01.hyp.37.4.1053 · Cited by 1,344
A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease
Pepine, C. J., Handberg, E. M., Cooper‐DeHoff, R. M., Marks, R. G., Kowey, P. R., Messerli, F. H., Mancia, G., Cangiano, J. L., García-Barreto, D., Keltai, M., et al. (2003) · JAMA · doi:10.1001/jama.290.21.2805 · Cited by 1,278
Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
Brown, M. J., Palmer, C. R., Castaigne, A., de Leeuw, P. W., Mancia, G., Rosenthal, T., & Ruilope, L. M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02527-7 · Cited by 1,206
Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus
Gress, T. W., Nieto, F. J., Shahar, E., Wofford, M. R., & Brancati, F. L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003303421301 · Cited by 1,202
A Comparison of Outcomes with Angiotensin-Converting–Enzyme Inhibitors and Diuretics for Hypertension in the Elderly
Wing, L. M. H., Reid, C. M., Ryan, P., Beilin, L. J., Brown, M. A., Jennings, G. L. R., Johnston, C. I., McNeil, J. J., Macdonald, G. J., Marley, J. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021716 · Cited by 1,130
Self-citation
CHARM IN-VESTIGATORS AND COMMITTEES. EFFECTS OF CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED LEFT-VENTRICULAR SYSTOLIC FUNCTION TAKING ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS: THE CHARM-ADDED TRIAL
McMurray, J. J. V., Östergren, J., Swedberg, K. B., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer (2003) · The Lancet · Cited by 1,043
Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study
Hansson, L., Hedner, T., Lund‐Johansen, P., Kjeldsen, S. E., Lindholm, L. H., Syvertsen, J. O., Lanke, J., Fairé, U. D., Dahlöf, B., & Karlberg, B. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02526-5 · Cited by 903
Glucose Toxicity in β-Cells: Type 2 Diabetes, Good Radicals Gone Bad, and the Glutathione Connection
Robertson, R. P., Harmon, J., Tran, P. O., Tanaka, Y., & Takahashi, H. (2003) · Diabetes · doi:10.2337/diabetes.52.3.581 · Cited by 897
A Comparison of the Effects of Hydrochlorothiazide and Captopril on Glucose and Lipid Metabolism in Patients with Hypertension
Pollare, T., Lithell, H., & Berne, C. (1989) · New England Journal of Medicine · doi:10.1056/nejm198909283211305 · Cited by 851
Ramipril and the Development of Diabetes
Yusuf, S. (2001) · JAMA · doi:10.1001/jama.286.15.1882 · Cited by 541
Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects
Verdecchia, P., Reboldi, G., Angeli, F., Borgioni, C., Gattobigio, R., Filippucci, L., Norgiolini, S., Bracco, C., & Porcellati, C. (2004) · Hypertension · doi:10.1161/01.hyp.0000125726.92964.ab · Cited by 510
Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures
Svensson, P., Fairé, U. D., Sleight, P., Yusuf, S., & Östergren, J. (2001) · Hypertension · doi:10.1161/hy1101.099502 · Cited by 490
Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes.
Kahn, S. E., Andrikopoulos, S., & Verchere, C. B. (1999) · Diabetes · doi:10.2337/diabetes.48.2.241 · Cited by 488
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
Lindholm, L. H., Ibsen, H., Borch-Johnsen, K., Olsen, M. H., Wachtell, K., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., et al. (2002) · Journal of Hypertension · doi:10.1097/00004872-200209000-00035 · Cited by 392
Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: Effects of ACEI and ARB
Onozato, M. L., Tojo, A., Goto, A., Fujita, T., & Wilcox, C. S. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00123.x · Cited by 374
Metabolic outcome during 1 year in newly detected hypertensives
Lindholm, L. H., Persson, M., Alaupovic, P., Carlberg, B., Svensson, A., & Samuelsson, O. G. (2003) · Journal of Hypertension · doi:10.1097/00004872-200308000-00022 · Cited by 353
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and Evidence From New Hypertension Trials
Jones, D. W., & Hall, J. E. (2003) · Hypertension · doi:10.1161/01.hyp.0000110061.06674.ca · Cited by 309
Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).
Lindholm, L. H., Persson, M., Alaupovic, P., Carlberg, B., Svensson, A., & Samuelsson, O. G. (2003) · PubMed · doi:10.1097/01.hjh.0000084723.53355.76 · Cited by 308
Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats
Carlsson, P., Berne, C., & Jansson, L. E. (1998) · Diabetologia · doi:10.1007/s001250050880 · Cited by 305
The EUROPA trial
Fox, K. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14974-4 · Cited by 297
Selective Angiotensin II Receptor Antagonism Reduces Insulin Resistance in Obese Zucker Rats
Henriksen, E. J., Jacob, S., Kinnick, T. R., Teachey, M. K., & Krekler, M. (2001) · Hypertension · doi:10.1161/hy1101.092970 · Cited by 293
Improved Islet Morphology after Blockade of the Renin- Angiotensin System in the ZDF Rat
Tikellis, C., Wookey, P. J., Candido, R., Andrikopoulos, S., Thomas, M. C., & Cooper, M. E. (2004) · Diabetes · doi:10.2337/diabetes.53.4.989 · Cited by 285
Self-citation
Reduction of the Accumulation of Advanced Glycation End Products by ACE Inhibition in Experimental Diabetic Nephropathy
Forbes, J. M., Cooper, M. E., Thallas, V., Burns, W. C., Thomas, M. C., Brammar, G. C., Lee, F., Grant, S. L., Burrell, L. M., Jerums, G., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.11.3274 · Cited by 278
Self-citation
Enalapril Reduces the Incidence of Diabetes in Patients With Chronic Heart Failure: Insight From the Studies Of Left Ventricular Dysfunction (SOLVD)
Vermes, E., Ducharme, A., Bourassa, M. G., Lessard, M., White, M., & Tardif, J.-C. (2003) · Circulation · doi:10.1161/01.cir.0000054611.89228.92 · Cited by 248
Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease
McFarlane, S. I., Kumar, A., & Sowers, J. R. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00432-6 · Cited by 246
Pancreatic β-Cells Express Phagocyte-Like NAD(P)H Oxidase
Oliveira, H. R., Verlengia, R., Carvalho, C. R. D. O., Britto, L. R., Curi, R., & Carpinelli, Â. R. (2003) · Diabetes · doi:10.2337/diabetes.52.6.1457 · Cited by 186
NAD(P)H Oxidase-derived Hydrogen Peroxide Mediates Endothelial Nitric Oxide Production in Response to Angiotensin II
Cai, H. “., Li, Z., Dikalov, S., Holland, S. M., Hwang, J., Jo, H., Dudley, S. C., & Harrison, D. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208884200 · Cited by 182
Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes
Gilbert, R. E., Kelly, D. J., Cox, A. J., Wilkinson‐Berka, J. L., Rumble, J. R., Osicka, T. M., Panagiotopoulos, S., Lee, V. W., Hendrich, E., Jerums, G., et al. (2000) · Diabetologia · doi:10.1007/s001250051539 · Cited by 179
Self-citation
From the hope to the ontarget and the transcend studies: challenges in improving prognosis
Yusuf, S. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02323-2 · Cited by 169
The tissue renin-angiotensin system in human pancreas
Tahmasebi, M., Puddefoot, Inwang, E., & Vinson, G. P. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1610317 · Cited by 153
Captopril enhances insulin responsiveness of forearm muscle tissue in non‐insulin‐dependent diabetes mellitus
Jauch, K. ‐., Hartl, W. H., Guenther, B., WICKLMAYR, M., Kristian, R. E. T. T., & Dietze, G. (1987) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1987.tb01141.x · Cited by 140
Crosstalk between insulin and angiotensin II signalling systems
Folli, F. B., Saad, M. J. A., Velloso, L. A., Hansen, H. F., Carandente, O., Feener, E. P., & Kahn, C. R. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1212088 · Cited by 139
Antihypertensive treatment in patients with type-2 diabetes mellitus
Zanchetti, A., & Ruilope, L. M. (2002) · Journal of Hypertension · doi:10.1097/00004872-200211000-00001 · Cited by 133
ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients.
Paolisso, G., Gambardella, A., Verza, M., D’Amore, A., Sgambato, S., & Varricchio, M. T. (1992) · PubMed · Cited by 125
Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance
Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Pettiti, M., Natali, A., Mari, A., & DeFronzo, R. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1169-6 · Cited by 123
Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats
Kuno, A., Yamada, T., Masuda, K., Ogawa, K., Sogawa, M., Nakamura, S., Nakazawa, T., Ohara, H., Nomura, T., Joh, T., et al. (2003) · Gastroenterology · doi:10.1053/gast.2003.50147 · Cited by 122
Obesity-associated activation of angiotensin and endothelin in the cardiovascular system
Barton, M., Carmona, R., Ortmann, J., Krieger, J. E., & Traupe, T. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00307-2 · Cited by 113
ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with Type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension
Torlone, E., Rambotti, A. M., Perriello, G., Botta, G., Santeusanio, F., Brunetti, P., & Bolli, G. B. (1991) · Diabetologia · doi:10.1007/bf00500383 · Cited by 113
Hypertension and diabetes
Jandeleit-Dahm, K. A. M., & Cooper, M. E. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200203000-00014 · Cited by 107
Self-citation
Development of diabetes is retarded by ACE inhibition in hypertensive patients ??? a subanalysis of the Captopril Prevention Project (CAPPP)
Niklason, A., Hedner, T., NISKANEN, L. K., & Lanke, J. (2004) · Journal of Hypertension · doi:10.1097/00004872-200403000-00029 · Cited by 91
Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE
Gerstein, H. C. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.285 · Cited by 89
Ramipril treatment suppresses islet fibrosis in Otsuka Long–Evans Tokushima fatty rats
Ko, S., Kwon, H., Kim, S., Moon, S. D., Ahn, Y., Song, K., Son, H.-S., Cha, B., Lee, K., Son, H., et al. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.02.023 · Cited by 87
Insulin-Induced Glucose Transporter (GLUT1 and GLUT4) Translocation in Cardiac Muscle Tissue Is Mimicked by Bradykinin
Kristian, R. E. T. T., WICKLMAYR, M., Dietze, G., & Häring, H.-U. (1996) · Diabetes · doi:10.2337/diab.45.1.s66 · Cited by 84
Renal expression of transforming growth factor-β inducible gene-h3 (βig-h3) in normal and diabetic rats
Gilbert, R. E., Wilkinson‐Berka, J. L., Johnson, D. W., Cox, A. J., Soulis, T., Wu, L. L., Kelly, D. J., Jerums, G., Pollock, C. A., & Cooper, M. E. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00081.x · Cited by 79
Self-citation
A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients
Lender, D. (1999) · American Journal of Hypertension · doi:10.1016/s0895-7061(98)00259-3 · Cited by 79
Bradykinin potentiates insulin-stimulated glucose uptake and enhances insulin signal through the bradykinin B2 receptor in dog skeletal muscle and rat L6 myoblasts
Miyata, T., Taguchi, T., Uehara, M., Isami, S., Kishikawa, H., Kaneko, K. B., Araki, E., & Shichiri, M. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1380344 · Cited by 78
Optimizing Treatment of Hypertension in Patients With Diabetes
Cooper, M. E. (2000) · JAMA · doi:10.1001/jama.283.24.3177 · Cited by 71
Self-citation
Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle
Jacob, S., Henriksen, E. J., Fogt, D. L., & Dietze, G. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90021-9 · Cited by 69
Connective Tissue Growth Factor Is Up-Regulated in the Diabetic Retina: Amelioration by Angiotensin-Converting Enzyme Inhibition
Tikellis, C., Cooper, M. E., Twigg, S. M., Burns, W. C., & Tolcos, M. (2003) · Endocrinology · doi:10.1210/en.2003-0967 · Cited by 66
Self-citation
Potential Role of Bradykinin in Forearm Muscle Metabolism in Humans
Dietze, G., WICKLMAYR, M., Kristian, R. E. T. T., Jacob, S., & Henriksen, E. J. (1996) · Diabetes · doi:10.2337/diab.45.1.s110 · Cited by 63
Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance
Henriksen, E. J., & Jacob, S. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00265.x · Cited by 61
Association between antihypertensive drug use and hypoglycemia: A case-control study of diabetic users of insulin or sulfonylureas
Thamer, M., Ray, N. F., & Taylor, T. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(99)80039-3 · Cited by 58
Preventing Type II Diabetes Mellitus
Prisant, L. M. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004263018 · Cited by 58
Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance
Ponte, D. B. D., Fogt, D. L., Jacob, S., & Henriksen, E. J. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90355-9 · Cited by 52
The ongoing telmisartan alone and in combination with ramipril global endpoint trial program
Unger, T. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00230-3 · Cited by 51
Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension
Higashiura, K., Ura, N., Miyazaki, Y., & Shimamoto, K. (1999) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000748 · Cited by 50
Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure
Reaven, G. M., Clinkingbeard, C., Jeppesen, J., Maheux, P., Pei, D., FOOTE, J., Hollenbeck, C. B., & Chen, Y. I. (1995) · American Journal of Hypertension · doi:10.1016/0895-7061(95)00055-t · Cited by 48
Nitric oxide release in rat skeletal muscle capillary
Mitchell, D. J., & Tyml, K. (1996) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1996.270.5.h1696 · Cited by 43
Insulin Sensitivity in Obese Hypertensive Dyslipidemic Patients Treated with Enalapril or Atenolol
Morel, Y., Gadient, A., Keller, U., Vadas, L., & Golay, A. (1995) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199508000-00017 · Cited by 42
Angiotensin in atherosclerosis
Kon, V., & Jabs, K. L. (2004) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200405000-00005 · Cited by 42
The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM
Shamiss, A., CARROLL, J., Peleg, E., Grossman, E., & Rosenthal, T. (1995) · American Journal of Hypertension · doi:10.1016/0895-7061(94)00181-a · Cited by 41
Trandolapril Does Not Improve Insulin Sensitivity in Patients with Hypertension and Type 2 Diabetes: A Double-Blind, Placebo-Controlled Crossover Trial1
Petrie, J. R., Morris, A. D., Ueda, S., SMALL, M. P., Donnelly, R., Connell, J., & Elliott, H. L. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.5.6599 · Cited by 35
Metabolic issues in the antihypertensive and lipid-lowering heart attack trial study
Punzi, H. A., & Punzi, C. F. (2004) · Current Hypertension Reports · doi:10.1007/s11906-004-0084-7 · Cited by 34
Four week administration of an ACE inhibitor and a cardioselective β‐blocker in healthy volunteers: no influence on insulin sensitivity
Heinemann, L., Heise, T., Ampudia‐Blasco, F. J., Sawicki, P. T., Šindelka, G., BRUNNER, G., & Starke, A. A. R. (1995) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1995.tb01751.x · Cited by 29
The effect of angiotensin‐l converting enzyme inhibition on insulin action in healthy volunteers
Gans, R. O. B., Bilo, H. J. G., Nauta, J. J. P., Popp‐Snijders, C., Heine, R. J., & Donker, A. J. M. (1991) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1991.tb01405.x · Cited by 28
Role of angiotensin-converting enzyme inhibition in glucose metabolism and renal injury in diabetes
Velasquez, M. T., Bhathena, S. J., Striffler, J. S., Thibault, N., & Scalbert, E. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90363-8 · Cited by 25
Normalization of Insulin Resistance in Non-Obese Essential Hypertension by Cilazapril Treatment
Suzuki, M., Ikebuchi, M., Yokota, C., Shinozaki, K., & Harano, Y. (1995) · Clinical and Experimental Hypertension · doi:10.3109/10641969509037407 · Cited by 25
When Does New Onset Diabetes Resulting From Antihypertensive Therapy Increase Cardiovascular Risk
Bakris, G. L., & Sowers, J. R. (2004) · Hypertension · doi:10.1161/01.hyp.0000125727.92964.e2 · Cited by 23
Alterations of non-enzymatic biochemistry in uremia, diabetes, and atherosclerosis ("carbonyl stress").
Miyata, T. (2002) · PubMed · Cited by 22
Diabetes and cardiovascular outcomes in elderly subjects treated with ace-inhibitors or diuretics: findings from the 2ND Australian national blood pressure study
Reid, C. M. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)00110-9 · Cited by 20
Self-citation
Improvement in Metabolic Risk Factors for Coronary Heart Disease Associated With Cilazapril Treatment
Shieh, S.-M., Sheu, W. H., Shen, D. D.-C., Fuh, M. M.-T., Jeng, C.-Y., Jeng, J. R., Chen, Y. I., & Reaven, G. M. (1992) · American Journal of Hypertension · doi:10.1093/ajh/5.8.506 · Cited by 20
Insulin Sensitivity in Patients with Essential Hypertension: No Influence of the ACE Inhibitor Enalapril
Heise, T., Heinemann, L., Kristahn, K., Berger, M., & Sawicki, P. T. (1999) · Hormone and Metabolic Research · doi:10.1055/s-2007-978766 · Cited by 18
Trandolapril Does Not Improve Insulin Sensitivity in Patients with Hypertension and Type 2 Diabetes: A Double-Blind, Placebo-Controlled Crossover Trial
Petrie, J. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.5.1882 · Cited by 17
Untitled work
Alberti (1998) · doi:10.1002/(sici)1096-9136(199807)15:7

Research works printed but not linked: 3

2000, Heart Outcomes Prevention Evaluation Study Investigators., Lancet, 355, 253
1999, National Intervention Cooperative Study in Elderly Hypertensives Study Group., Hypertension, 34, 1129
1997, Diabetes C, are, 20, 1183

Sorted by citations

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis
Elliott, W. J., & Meyer, P. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60108-1 · Cited by 1,016
Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention
Schrader, J., Lüders, S., Kulschewski, A., Hammersen, F., Plate, K., Berger, J., Zidek, W., Dominiak, P., Diener, H., & the MOSES Study Group (2005) · Stroke · doi:10.1161/01.str.0000166048.35740.a9 · Cited by 766
Targeting inflammation in the treatment of type 2 diabetes: time to start
Donath, M. Y. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4275 · Cited by 690
Effect of valsartan on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001121 · Cited by 660
Renin-angiotensin system and cardiovascular risk
Schmieder, R. E., Hilgers, K. F., Schlaich, M. P., & Schmidt, B. M. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60242-6 · Cited by 675

See all 293

Authors: Jandeleit-Dahm, K. A., Tikellis, C., Reid, C. M., Johnston, C. I., & Cooper, M. E.
Affiliations: Baker Heart and Diabetes Institute (AU)
ORCID: Reid, Christopher M
Cooper, Mark E
Venue: Journal of Hypertension
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2005-03
Volume: 23
Issue: 3
Pages: 463-473
ISSN: 0263-6352 (ISSN-L)
DOI: 10.1097/01.hjh.0000160198.05416.72
OpenAlex: W2048359273
Cited by: 293
References: 89
Citations by year: 2026: 2 · 2025: 5 · 2024: 4 · 2023: 6 · 2022: 8 · 2021: 4 · 2020: 11 · 2019: 7 · 2018: 15 · 2017: 7 · 2016: 3 · 2015: 10 · 2014: 14 · 2013: 8 · 2012: 17
FWCI: 6.04
Type: journal article
Language: en
Open access: closed
Locations: Journal of Hypertension (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords: renin-angiotensin system, ACE inhibitors, angiotensin receptor blockers, type 2 diabetes prevention, new-onset diabetes, insulin resistance, beta-cell death, angiotensin II, hypertension, obesity, antihypertensive drugs, calcium channel blockers, combination antihypertensive therapy
MeSH terms: Angiotensin-Converting Enzyme Inhibitors, Diabetes Mellitus, Type 2, Humans, Hypertension, Renin-Angiotensin System, Incidence, Angiotensin II Type 1 Receptor Blockers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks